Quality of Life as an Integrative Indicator of Health Status in Patients with Chronic Hepatitis C and Concomitant Diabetes Mellitus Type II
Abstract
The main indicators of quality of life in patients with chronic hepatitis C with concomitant diabetes mellitus type II were studied on the basis of SF-36. A sharp decrease in physical and mental health was observed in patients with combined comorbidity in comparison with the group of patients without concomitant diabetes mellitus type II. Improvement of the patients’ quality of life by all parameters was detected under the influence of alpha-lipoic acid and lactulose use in addition to antiviral therapy.
References
Anastasiy IA. 60 konferentsiya amerikanskogo obshchestva po izucheniyu boleznei pecheni. Suchasni infektsii. 2010;1:127–133
Borisov VA, Sanin BI, Samsonova SE. [The experience of domestic antiviral agents, and some of own approaches in the treatment of chronic hepatitis C in adults]. Epidemiologiya i infektsionnye bolezni. 2015;3:4–10
Byeverov AO, Maevskaya MV. Khronicheskiy hepatit C i sochetannaya patologiya pecheni. Klinicheskie perspektivy hastroenterologii, hepatologii. 2008;6:9–17
Beloborodova EI, Lambrova EG, Beloborodova EV, et al. Pokazateli kachestva zhyzni u patsientov s khronicheskimi virusnymi hepatitami. Terapevticheskiy arkhiv. 2010;82 (11):41–45
Derbak MA. [Treatment of chronic hepatitis C in patients with diabetes type 2]. Naukovyi visnyk Uzhhorodskoho universytetu. 2013;1:24–27
Drapchak IM. Features of life quality evaluation in people with chronic liver diseases. Galic'kij likars'kij visnik. 2015;22 (4):16–19
Zhidkikh VN. Hepatit C – problema sovremennoi meditsiny (letsiya dlya vrachei). Medyko-sotsialni problem simii. 2009;14 (3):254–261
Kozko VN, Antsyferova NV, Solomennik AO. [Clinical and epidemiological features of chronic hepatitis C at present]. Mezhdunarodnyi meditsinskiy zhurnal. 2013;3:69–72
Kuznetsova AV, Dyachenko SV, Ostrovskiy AB, et al. Sravnitelnyi ekonomicheskiy analiz izmeneniya kachestva zhyzni pod vliyaniem pegilirovannykh interferonov pri khronicheskom hepatite C. Klinicheskie perspektivy hastroenterologii, hepatologii. 2012;5:41–46
Serheeva TA. Hepatyt C: vid spetsyfichnoi diahnostyky do kontroliu nad infektsiieiu. Profilaktychna medytsyna. 2014;3-4:80–81
Ushenina LA, Ryabokon OV. [Clinical-biochemical and morphological features of chronic hepatitis C at infectious different genotypes HCV]. Patolohiia. 2009;6 (1):86–89
Romero-Gomez M. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128(3):636–641. DOI: http://doi.org/10.1053/j.gastro.2004.12.049 [PMid: 15765399]
Ware JE, Snow KK, Kosinski MM, Gandek B. SF–36 Health Survey. Manual and interpretation guide. Boston, Mass: The Health Institute, New England Medical Center; 1993. 218 p.

Copyright (c) 2016 Oleksandra Marynchak, Oleksandra Pryshliak, Oksana Kopchak, Iryna Hrynchychyn, Ludmyla Byderkevych

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).